Edition:
United States

Magforce AG (MF6G.F)

MF6G.F on Frankfurt Stock Exchange

4.15EUR
23 Sep 2016
Change (% chg)

-- (--)
Prev Close
€4.15
Open
€4.18
Day's High
€4.18
Day's Low
€4.15
Volume
435
Avg. Vol
9,132
52-wk High
€5.90
52-wk Low
€3.95

Latest Key Developments (Source: Significant Developments)

MagForce FY net loss widens to EUR 1.5 mln
Friday, 1 Jul 2016 01:58am EDT 

MagForce AG : Said on Thursday FY net loss was at 1.5 million euros ($1.66 million), so that is 0.5 million euros above the previous year (2014: 1.0 million euros) . FY sales revenues amounted to 2.6 million euros (2014: no revenues) . Expects a markable reduction of the net loss for the fiscal year 2016 .With its liquidity and current plans, the Company will be able to cover its operating expenses through 2017.  Full Article

MagForce AG: initiation of Commercial NanoTherm treatments for brain cancer
Tuesday, 26 Apr 2016 02:29am EDT 

MagForce AG:Announces initiation of Commercial NanoTherm treatments for brain cancer at Vivantes Friedrichshain in collaboration with Charité - Universitaetsmedizin Berlin.  Full Article

MagForce AG confirms FY 2015 outlook
Wednesday, 30 Sep 2015 04:05pm EDT 

MagForce AG:Reaffirms FY 2015 outlook, sees net loss for FY 2015 to be higher than in 2014.  Full Article

MagForce AG comments on FY 2015 earnings guidance
Tuesday, 30 Jun 2015 12:51pm EDT 

MagForce AG:Says that it expects the net loss for FY 2015 to be higher than in FY 2014.This increase is due to the discontinuation of special measures taken in 2014 from the out-licensing of distribution rights and to increased commercialization efforts, which can be seen in the context of the corresponding focus of the company on key strategic value drivers.  Full Article

MagForce AG says Magforce USA files investigational device exemption for Nanotherm therapy
Thursday, 21 May 2015 01:15am EDT 

MagForce AG:Magforce USA, inc. files investigational device exemption for Nanotherm Therapy to treat intermediate risk prostate cancer.Purpose of proposed study is to demonstrate that Nanotherm can ablate cancer lesions for patients who have gleason score 7 prostate cancer and are under active surveillance.  Full Article

MagForce AG completes capital increase at 6.00 euros per share
Friday, 21 Nov 2014 03:31am EST 

MagForce AG:Says completes capital increase at a price of 6.00 euros per new share.Says has successfully placed 1.7 million new shares at 6.00 euros per share against cash contribution with qualified investors raising proceeds in amount of 10.2 million euros.  Full Article

MagForce AG to issue up to 1,700,000 new shares in capital increase
Thursday, 20 Nov 2014 12:23pm EST 

MagForce AG:Announces capital increase excluding shareholders' subscription rights.Says will utilize portion of authorized capital by issuing up to 1,700,000 new shares representing about 7 pct of registered share capital.Says proceeds shall be utilized to accelerate commercialization of Nanotherm therapy outside of North America.Says placement of new shares is expected to be completed on Nov. 21, 2014.  Full Article

MagForce AG announces filing of pre-submission for MagForce's NanoTherm focal therapy for intermediate risk prostate cancer
Tuesday, 11 Nov 2014 03:23am EST 

MagForce AG:Announces together with its subsidiary MagForce USA, that MagForce USA, Inc. has filed with U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health, NanoTherm Therapy pre-submission describing its focal treatment for prostate cancer.Says this is the second filing following NanoTherm Therapy pre-submission of Dec. 2013 relating to recurrent Glioblastoma multiforme.  Full Article

BRIEF-MagForce FY net loss widens to EUR 1.5 mln

* Said on Thursday FY net loss was at 1.5 million euros ($1.66 million), so that is 0.5 million euros above the previous year (2014: 1.0 million euros)